- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Ophthalmology
Volume 2012 (2012), Article ID 831502, 7 pages
New Treatments for Bacterial Keratitis
1Eye Institute, The University of Hong Kong, Room 301, Level 3, Block B, 100 Cyberport Road, Cyberport 4, Hong Kong
2Department of Ophthalmology, Queen Mary Hospital, Hong Kong
Received 31 May 2012; Revised 30 July 2012; Accepted 19 August 2012
Academic Editor: Rajesh Sinha
Copyright © 2012 Raymond L. M. Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. B. Jones, “Decision-making in the management of microbial keratitis,” Ophthalmology, vol. 88, no. 8, pp. 814–820, 1981.
- F. Stapleton, K. Edwards, L. Keay, et al., “Risk factors for moderate and severe microbial keratitis in daily wear contact lens users,” Ophthalmology, vol. 119, no. 8, pp. 1516–1521, 2012.
- M. Ahn, K. C. Yoon, S. K. Ryu, N. C. Cho, and I. C. You, “Clinical aspects and prognosis of mixed microbial (bacterial and fungal) keratitis,” Cornea, vol. 30, no. 4, pp. 409–413, 2011.
- G. Amescua, D. Miller, and E. C. Alfonso, “What is causing corneal ulcer? Management strategies for unresponsive corneal ulceration,” Eye, vol. 26, pp. 28–36, 2012.
- M. J. Bharathi, R. Ramakrishnan, R. Meenakshi, C. Shivakumar, and L. Lional Raj, “Analysis of the risk factors predisposing to fungal, bacterial & Acanthamoeba keratitis in south India,” Indian Journal of Medical Research, vol. 130, no. 6, pp. 749–757, 2009.
- American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Pattern Guidelines, Bacterial Keratitis—Limited Revision, San Francisco, Calif, USA, American Academy of Ophthalmology, 2011, http://one.aao.org/CE/PracticeGuidelines/PPP.aspx.
- S. B. Levy, “Multidrug resistance: a sign of the times,” The New England Journal of Medicine, vol. 338, no. 19, pp. 1376–1377, 1998.
- G. P. DeMuri and M. K. Hostetter, “Resistance to antifungal agents,” Pediatric Clinics of North America, vol. 42, no. 3, pp. 665–685, 1995.
- H. C. Neu, “The crisis in antibiotic resistance,” Science, vol. 257, no. 5073, pp. 1064–1073, 1992.
- H. G. B. Bennett, J. Hay, C. M. Kirkness, D. V. Seal, and P. Devonshire, “Antimicrobial management of presumed microbial keratitis: guidelines for treatment of central and peripheral ulcers,” British Journal of Ophthalmology, vol. 82, no. 2, pp. 137–145, 1998.
- E. Pestova, J. J. Millichap, G. A. Noskin, and L. R. Peterson, “Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 5, pp. 583–590, 2000.
- J. M. Blondeau, “Fluoroquinolones: mechanism of action, classification, and development of resistance,” Survey of Ophthalmology, vol. 49, supplement 2, pp. S73–S78, 2004.
- M. H. Goldstein, R. P. Kowalski, and Y. J. Gordon, “Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review,” Ophthalmology, vol. 106, no. 7, pp. 1313–1318, 1999.
- G. Alexandrakis, E. C. Alfonso, and D. Miller, “Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones,” Ophthalmology, vol. 107, no. 8, pp. 1497–1502, 2000.
- L. M. Fisher, V. J. Heaton, H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel, “Dual activity of fluoroquinolones against Streptococcus pneumoniae,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 2, pp. 463–465, 2003.
- L. Huelves, D. Sevillano, C. Martínez-Marín et al., “Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones,” International Journal of Antimicrobial Agents, vol. 27, no. 4, pp. 294–299, 2006.
- M. Tanaka, T. Wang, Y. Onodera, Y. Uchida, and K. Sato, “Mechanism of quinolone resistance in Staphylococcus aureus,” Journal of Infection and Chemotherapy, vol. 6, no. 3, pp. 131–139, 2000.
- D. C. Hooper, “Fluoroquinolone resistance among Gram-positive cocci,” Lancet Infectious Diseases, vol. 2, no. 9, pp. 530–538, 2002.
- Ciloxan [package insert], Fort Worth, Tex, Alcon Laboratories, Inc., 2006.
- Ocuflox [package insert], Irvine, Calif, Allergan, Inc., 2002.
- R. P. Kowalski, D. K. Dhaliwal, L. M. Karenchak et al., “Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates,” American Journal of Ophthalmology, vol. 136, no. 3, pp. 500–505, 2003.
- H. Sueke, S. Kaye, T. Neal et al., “Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis,” Investigative Ophthalmology and Visual Science, vol. 51, no. 5, pp. 2519–2524, 2010.
- B. Chawla, P. Agarwal, R. Tandon et al., “In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones,” European Journal of Ophthalmology, vol. 20, no. 2, pp. 300–305, 2010.
- A. Duggirala, J. Joseph, S. Sharma, R. Nutheti, P. Garg, and T. Das, “Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison,” Indian Journal of Ophthalmology, vol. 55, no. 1, pp. 15–19, 2007.
- S. Ramesh, R. Ramakrishnan, M. Jayahar Bharathi, M. Amuthan, and S. Viswanathan, “Prevalence of bacterial pathogens causing ocular infections in South India,” Indian Journal of Pathology and Microbiology, vol. 53, no. 2, pp. 281–286, 2010.
- M. J. Bharathi, R. Ramakrishnan, C. Shivakumar, R. Meenakshi, and D. Lionalraj, “Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India,” Indian Journal of Ophthalmology, vol. 58, no. 6, pp. 497–507, 2010.
- A. D. D. Oliveira, P. A. D'Azevedo, W. Francisco, and A. L. Höfling-Lima, “In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil,” Cornea, vol. 26, no. 2, pp. 194–198, 2007.
- M. Constantinou, M. Daniell, G. R. Snibson, H. T. Vu, and H. R. Taylor, “Clinical efficacy of moxifloxacin in the treatment of Bacterial keratitis. A randomized clinical trial,” Ophthalmology, vol. 114, no. 9, pp. 1622–1629, 2007.
- P. Parmar, A. Salman, C. M. Kalavathy et al., “Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis,” American Journal of Ophthalmology, vol. 141, no. 2, pp. 282–286, 2006.
- V. M. Shah, R. Tandon, G. Satpathy et al., “Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers,” Cornea, vol. 29, no. 7, pp. 751–757, 2010.
- E. Spoerl, M. Huhle, and T. Seiler, “Induction of cross-links in corneal tissue,” Experimental Eye Research, vol. 66, no. 1, pp. 97–103, 1998.
- E. Spoerl and T. Seiler, “Techniques for stiffening the cornea,” Journal of Refractive Surgery, vol. 15, no. 6, pp. 711–713, 1999.
- G. Wollensak, E. Spoerl, and T. Seiler, “Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking,” Journal of Cataract and Refractive Surgery, vol. 29, no. 9, pp. 1780–1785, 2003.
- E. Spoerl, G. Wollensak, and T. Seiler, “Increased resistance of crosslinked cornea against enzymatic digestion,” Current Eye Research, vol. 29, no. 1, pp. 35–40, 2004.
- A. Tsugita, Y. Okada, and K. Uehara, “Photosensitized inactivation of ribonucleic acids in the presence of riboflavin,” Biochimica et Biophysica Acta, vol. 103, no. 2, pp. 360–363, 1965.
- P. H. Ruane, R. Edrich, D. Gampp, S. D. Keil, R. L. Leonard, and R. P. Goodrich, “Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light,” Transfusion, vol. 44, no. 6, pp. 877–885, 2004.
- R. P. Goodrich, R. A. Edrich, L. L. Goodrich, et al., “The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine,” in Flavins: Photochemistry and Photobiology. Royal Society of Chemistry, E. Silva and A. M. Edwards, Eds., vol. 6 of Comprehensive Series in Photochemistry and Photobiology, Cambridge, UK, 2006.
- R. P. Goodrich, R. A. Edrich, J. Li, and J. Seghatchian, “The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends,” Transfusion and Apheresis Science, vol. 35, no. 1, pp. 5–17, 2006.
- S. Marschner and R. Goodrich, “Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light,” Transfusion Medicine and Hemotherapy, vol. 38, no. 1, pp. 8–18, 2011.
- I. L. Schechmeister, “Sterilization by ultraviolet irradiation,” in Disinfection, Sterilization and Preservation, S. S. Block, Ed., pp. 553–565, Lea, Febiger, Philadelphia, Pa, USA, 4th edition, 1991.
- A. D. Russell, “Radiation sterilization,” in Principles and Practice of Disinfection, Preservation and Sterilization, A. G. Russell, W. B. Hugo, and G. A. J. Ayliffe, Eds., pp. 675–702, Blackwell Science, Oxford, UK, 3rd edition, 1999.
- K. Makdoumi, J. Mortensen, S. Crafoord, et al., “Infectious keratitis treated with corneal crosslinking,” Cornea, vol. 29, no. 12, pp. 1353–1358, 2010.
- G. Wollensak, “Crosslinking treatment of progressive keratoconus: new hope,” Current Opinion in Ophthalmology, vol. 17, no. 4, pp. 356–360, 2006.
- H. P. Iseli, M. A. Thiel, F. Hafezi, J. Kampmeier, and T. Seiler, “Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts,” Cornea, vol. 27, no. 5, pp. 590–594, 2008.
- E. Spoerl, M. Mrochen, D. Sliney, S. Trokel, and T. Seiler, “Safety of UVA-riboflavin cross-linking of the cornea,” Cornea, vol. 26, no. 4, pp. 385–389, 2007.
- S. A. R. Martins, J. C. Combs, G. Noguera et al., “Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis,” Investigative Ophthalmology and Visual Science, vol. 49, no. 8, pp. 3402–3408, 2008.
- R. T. Kashiwabuchi, F. R. S. Carvalho, Y. A. Khan, et al., “Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of acanthamoeba trophozoites,” Investigative Ophthalmology & Visual Science, vol. 52, pp. 9333–9338, 2011.
- L. Garduño-Vieyra, C. R. Gonzalez-Sanchez, and S. E. Hernandez-Da Mota, “Ultraviolet-a light and riboflavin therapy for acanthamoeba keratitis: a case report,” Ophthalmology, vol. 2, pp. 291–295, 2011.
- Y. A. Khan, R. T. Kashiwabuchi, S. A. Martins et al., “Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive acanthamoeba keratitis. Report of 3 cases,” Ophthalmology, vol. 118, no. 2, pp. 324–331, 2010.
- G. Wollensak, E. Spoerl, and T. Seiler, “Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus,” American Journal of Ophthalmology, vol. 135, no. 5, pp. 620–627, 2003.
- L. Müller, M. A. Thiel, A. I. Kipfer-Kauer, and C. Kaufmann, “Corneal cross-linking as supplementary treatment option in melting keratitis: a case series,” Klin Monbl Augenheilkd, vol. 229, pp. 411–415, 2012.
- K. Makdoumi, J. Mortensen, O. Sorkhabi, et al., “UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, pp. 95–102, 2012.
- T. M. Ferrari, M. Leozappa, M. Lorusso, E. Epifani, and L. M. Ferrari, “Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report,” European Journal of Ophthalmology, vol. 19, no. 2, pp. 295–297, 2009.
- R. Mather, J. M. Stewart, T. Prabriputaloong, J. Wong, and S. D. McLeod, “The effect of cataract surgery on ocular levels of topical moxifloxacin,” American Journal of Ophthalmology, vol. 138, no. 4, pp. 554–559, 2004.
- E. Alfonso and J. Crider, “Ophthalmic infections and their anti-infective challenges,” Survey of Ophthalmology, vol. 50, no. 6, supplement 1, pp. S1–S6, 2005.
- R. S. Wagner, M. B. Abelson, A. Shapiro, and G. Torkildsen, “Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue,” Archives of Ophthalmology, vol. 123, no. 9, pp. 1282–1283, 2005.
- S. M. Robertson, M. A. Curtis, B. A. Schlech et al., “Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans,” Survey of Ophthalmology, vol. 50, no. 6, supplement 1, pp. S32–S45, 2005.
- R. Solomon, E. D. Donnenfeld, H. D. Perry et al., “Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor,” Ophthalmology, vol. 112, no. 3, pp. 466–469, 2005.
- D. H. Kim, W. J. Stark, T. P. O'Brien, and J. D. Dick, “Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients,” Ophthalmology, vol. 112, no. 11, pp. 1992–1996, 2005.
- E. J. Holland, S. S. Lane, T. Kim, M. Raizman, and S. Dunn, “Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty,” Cornea, vol. 27, no. 3, pp. 314–319, 2008.
- A. Chen, L. Prajna, M. Srinivasan et al., “Does in vitro susceptibility predict clinical outcome in bacterial keratitis?” American Journal of Ophthalmology, vol. 145, no. 3, pp. 409–412, 2008.
- Z. Shalchi, A. Gurbaxani, M. Baker, and J. Nash, “Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United Kingdom,” Ophthalmology, vol. 118, no. 11, pp. 2161–2165, 2011.